Abstract
A total of 73 patients with neuroleptic-resistant paranoid schizophrenia were studied. Patients were divided into two groups: a study group (37 patients) and a reference group (36 patients). Both groups of patients received standard psychopharmacotherapy. Patients of the study group also received a combination of Reamberin and Cycloferon. Before treatment, both groups of patients showed significant impairments to interferon status, characterized by decreases in serum interferon (sIFN) activity and blood α- and γ-interferon (IFN) levels. This combination of agents was found to have positive effects on both the clinical picture of the disease and on measures of interferon status, with normalization of sIFN activity and increases in blood α- and γ-IFN levels.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
